ClinicalTrials.gg

Program

filgotinib maleate

Its studies are mostly in Colitis, Ulcerative · Arthritis, Rheumatoid, led by Eisai.

Furthest: phase 4, since Sep 30, 20242 company-led studies, 1 open or runningNext primary completion: Nov 30, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai21 open or runningphase 4since Sep 30, 2024Sep 30, 2024Nov 30, 2027phase 4 · NCT06964113

Also a collaborator on its studies: Gilead Sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 30, 2024First study: phase 4 study in Arthritis, RheumatoidFirst studyNCT06625242 · 118 enrolled · South Korea
  2. May 2, 2025Phase 4 study in Colitis, UlcerativeNCT06964113 · 94 enrolled · South Korea

Ahead

  1. Nov 30, 2027Primary completion: phase 4 study in Colitis, UlcerativeNCT06964113

TargetBeta

“The maleate form of filgotinib, an orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinibruleLakefront Biotherapeutics NVphase 346
delgocitinibruleLEO Pharmaphase 321

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06964113Colitis, Ulcerative · South Korea4Active, not recruitingNov 30, 202794
NCT06625242Arthritis, Rheumatoid · South Korea4CompletedJan 21, 2026118

How it is read

Names in the registry

  • “Filgotinib Maleate”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.